KR20210105913A - 6,8-비스-벤질티오-옥탄산을 사용한 경구 요법 - Google Patents

6,8-비스-벤질티오-옥탄산을 사용한 경구 요법 Download PDF

Info

Publication number
KR20210105913A
KR20210105913A KR1020217019808A KR20217019808A KR20210105913A KR 20210105913 A KR20210105913 A KR 20210105913A KR 1020217019808 A KR1020217019808 A KR 1020217019808A KR 20217019808 A KR20217019808 A KR 20217019808A KR 20210105913 A KR20210105913 A KR 20210105913A
Authority
KR
South Korea
Prior art keywords
certain embodiments
cancer
benzylthio
bis
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217019808A
Other languages
English (en)
Korean (ko)
Inventor
로버트 쥐.엘. 쇼르
티모시 에스. 파디
라크말 보테주
Original Assignee
라파엘 파마슈티컬스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라파엘 파마슈티컬스, 인코포레이티드 filed Critical 라파엘 파마슈티컬스, 인코포레이티드
Publication of KR20210105913A publication Critical patent/KR20210105913A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020217019808A 2018-12-20 2019-12-20 6,8-비스-벤질티오-옥탄산을 사용한 경구 요법 Withdrawn KR20210105913A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862782938P 2018-12-20 2018-12-20
US62/782,938 2018-12-20
US201962834478P 2019-04-16 2019-04-16
US62/834,478 2019-04-16
PCT/US2019/067763 WO2020132401A1 (en) 2018-12-20 2019-12-20 Oral therapy using 6,8-bis-benzylthio-octanoic acid

Publications (1)

Publication Number Publication Date
KR20210105913A true KR20210105913A (ko) 2021-08-27

Family

ID=71101630

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217019808A Withdrawn KR20210105913A (ko) 2018-12-20 2019-12-20 6,8-비스-벤질티오-옥탄산을 사용한 경구 요법

Country Status (11)

Country Link
US (1) US20220040133A1 (https=)
EP (1) EP3897606A4 (https=)
JP (1) JP2022514084A (https=)
KR (1) KR20210105913A (https=)
CN (1) CN113543779A (https=)
AU (1) AU2019405976A1 (https=)
CA (1) CA3121645A1 (https=)
IL (1) IL283609A (https=)
MX (1) MX2021007324A (https=)
TW (1) TW202038930A (https=)
WO (1) WO2020132401A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240033277A1 (en) * 2020-12-03 2024-02-01 New York Society for the Relief of the Ruptured and Crippled, maintaining the Hospital for Special Methods for treating autoimmune diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263653B2 (en) * 2007-04-18 2012-09-11 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives
WO2009110859A1 (en) * 2008-03-04 2009-09-11 Robert Shorr Modulation of enzymatic structure, activity, and/or expression level
WO2011143590A1 (en) * 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
MA45865A (fr) * 2016-08-07 2021-04-14 Wistar Inst Procédés de détection et de traitement d'une tumeur exprimant pt346 pdk1
US20190160034A1 (en) * 2017-03-20 2019-05-30 Indiana University Research And Technology Corporation Use of ape1/ref-1 inhibitors in combination therapies for treatment of cancer
WO2019055525A1 (en) * 2017-09-12 2019-03-21 Raj Selvaraj FORMULATION OF SOLID NANOPARTICLES OF WATER-INSOLUBLE PHARMACEUTICAL SUBSTANCES WITH REDUCED OSTWALD CURING
US20210000778A1 (en) * 2018-04-16 2021-01-07 Rafael Pharmaceuticals, Inc. Therapeutic methods and compositions for treating prostate cancer using 6,8-bis-benzylthio-octanoic acid
CN112469405A (zh) * 2018-07-23 2021-03-09 拉斐尔制药股份有限公司 使用6,8-双(苄硫基)辛酸治疗胰腺癌的治疗方法和组合物
US20220054445A1 (en) * 2018-12-20 2022-02-24 Rafael Pharmaceuticals, Inc. Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor
MX2021011250A (es) * 2019-03-19 2022-02-11 Rafael Pharmaceuticals Inc Metodos y composiciones terapeuticas para tratar linfoma usando acido 6,8-bis-benciltio-octanoico.

Also Published As

Publication number Publication date
WO2020132401A1 (en) 2020-06-25
CN113543779A (zh) 2021-10-22
JP2022514084A (ja) 2022-02-09
AU2019405976A1 (en) 2021-06-24
US20220040133A1 (en) 2022-02-10
EP3897606A1 (en) 2021-10-27
EP3897606A4 (en) 2022-08-31
MX2021007324A (es) 2021-08-16
CA3121645A1 (en) 2020-06-25
IL283609A (en) 2021-07-29
TW202038930A (zh) 2020-11-01

Similar Documents

Publication Publication Date Title
TWI305527B (en) Synthesis of 4-(amino)-2-butenoyl chlorides and their use in the preparation of 3-cyano quinolines
TWI809503B (zh) Cdk4抑制劑之固體形式
RU2498804C2 (ru) Противоопухолевые комбинации из 4-анилино-3-цианохинолинов и капецитабина
ES2784843T3 (es) Complejos de Sirolimus y sus derivados, procedimiento para la preparación de los mismos y composiciones farmacéuticas que los contienen
JP6310144B2 (ja) がんを処置するための組み合わせ
JP2021521222A (ja) ６，８−ビス−ベンジルチオ−オクタン酸を使用して前立腺癌を治療するための治療方法および組成物
US20220054445A1 (en) Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor
CN115850248B (zh) 一种替尼类抗肿瘤药物化合物及其制备方法和应用
TWI825191B (zh) 尼拉帕尼（niraparib）游離鹼之結晶形
KR20210105913A (ko) 6,8-비스-벤질티오-옥탄산을 사용한 경구 요법
EP3860981A1 (en) Niraparib salts
CN113979954A (zh) 一种替尼类抗肿瘤药物化合物及其制备方法和应用
JP2022515171A (ja) ６，８－ビス－ベンジルチオ－オクタン酸および自食作用阻害剤を使用して癌を治療するための治療方法および組成物
EP4357340A1 (en) Salt of selective fgfr4 inhibitor, and preparation method therefor and application thereof
US20220331279A1 (en) Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and a glutaminase inhibitor
WO2026012350A1 (zh) 色烯酮类化合物的应用
HK40120176A (zh) 尼拉帕利盐
TW202114651A (zh) 用於治療癌症之方法及含有４，６—雙（苄硫基）己酸之藥物組成物
CN115120596A (zh) 一种喹唑啉化合物及药物组合物的应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203